Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Aug 6;400(10350):452-461.
doi: 10.1016/S0140-6736(22)01214-4.

Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study

Affiliations
Observational Study

Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study

Aranka V Ballering et al. Lancet. .

Abstract

Background: Patients often report various symptoms after recovery from acute COVID-19. Previous studies on post-COVID-19 condition have not corrected for the prevalence and severity of these common symptoms before COVID-19 and in populations without SARS-CoV-2 infection. We aimed to analyse the nature, prevalence, and severity of long-term symptoms related to COVID-19, while correcting for symptoms present before SARS-CoV-2 infection and controlling for the symptom dynamics in the population without infection.

Methods: This study is based on data collected within Lifelines, a multidisciplinary, prospective, population-based, observational cohort study examining the health and health-related behaviours of people living in the north of the Netherlands. All Lifelines participants aged 18 years or older received invitations to digital COVID-19 questionnaires. Longitudinal dynamics of 23 somatic symptoms surrounding COVID-19 diagnoses (due to SARS-CoV-2 alpha [B.1.1.7] variant or previous variants) were assessed using 24 repeated measurements between March 31, 2020, and Aug 2, 2021. Participants with COVID-19 (a positive SARS-CoV-2 test or a physician's diagnosis of COVID-19) were matched by age, sex, and time to COVID-19-negative controls. We recorded symptom severity before and after COVID-19 in participants with COVID-19 and compared that with matched controls.

Findings: 76 422 participants (mean age 53·7 years [SD 12·9], 46 329 [60·8%] were female) completed a total of 883 973 questionnaires. Of these, 4231 (5·5%) participants had COVID-19 and were matched to 8462 controls. Persistent symptoms in COVID-19-positive participants at 90-150 days after COVID-19 compared with before COVID-19 and compared with matched controls included chest pain, difficulties with breathing, pain when breathing, painful muscles, ageusia or anosmia, tingling extremities, lump in throat, feeling hot and cold alternately, heavy arms or legs, and general tiredness. In 12·7% of patients, these symptoms could be attributed to COVID-19, as 381 (21·4%) of 1782 COVID-19-positive participants versus 361 (8·7%) of 4130 COVID-19-negative controls had at least one of these core symptoms substantially increased to at least moderate severity at 90-150 days after COVID-19 diagnosis or matched timepoint.

Interpretation: To our knowledge, this is the first study to report the nature and prevalence of post-COVID-19 condition, while correcting for individual symptoms present before COVID-19 and the symptom dynamics in the population without SARS-CoV-2 infection during the pandemic. Further research that distinguishes potential mechanisms driving post-COVID-19-related symptomatology is required.

Funding: ZonMw; Dutch Ministry of Health, Welfare, and Sport; Dutch Ministry of Economic Affairs; University Medical Center Groningen, University of Groningen; Provinces of Drenthe, Friesland, and Groningen.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests We declare no competing interests.

Figures

Figure 1
Figure 1
Acute symptoms The shaded areas represent the SE of the moving average.
Figure 2
Figure 2
Core symptoms The shaded areas represent the SE of the moving average.
Figure 3
Figure 3
Other symptoms The shaded areas represent the SE of the moving average.

Comment in

Similar articles

Cited by

  • Long COVID: cognitive, balance, and retina manifestations.
    Carmona-Cervelló M, León-Gómez BB, Dacosta-Aguayo R, Lamonja-Vicente N, Montero-Alía P, Molist G, Ayet A, Chacón C, Costa-Garrido A, López-Lifante VM, Zamora-Putin V, Liutsko L, García-Sierra R, Fornés A, Moreno-Gabriel E, Massanella M, Muñoz-Moreno JA, Rodríguez-Pérez MC, Mateu L, Prats A, Mataró M, Boigues M, Quirant B, Prado JG, Martínez-Cáceres E, Violán C, Torán-Monserrat P; APC Collaborative Group. Carmona-Cervelló M, et al. Front Med (Lausanne). 2024 Jul 5;11:1399145. doi: 10.3389/fmed.2024.1399145. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39036098 Free PMC article.
  • Assessing the association between antibody status and symptoms of long COVID: A multisite study.
    Binswanger IA, Palmer-Toy DE, Barrow JC, Narwaney KJ, Bruxvoort KJ, Kraus CR, Lyons JA, Lam JA, Glanz JM. Binswanger IA, et al. PLoS One. 2024 Jun 6;19(6):e0304262. doi: 10.1371/journal.pone.0304262. eCollection 2024. PLoS One. 2024. PMID: 38843198 Free PMC article.
  • The prevalence of long COVID-19 syndrome in hospitalized patients with COVID-19 pneumonia.
    Petrakis V, Rafailidis P, Terzi I, Dragoumani I, Markatou F, Papanas N, Vradelis S, Gouveri E, Panopoulou M, Papazoglou D, Periklis P. Petrakis V, et al. Infez Med. 2024 Jun 1;32(2):202-212. doi: 10.53854/liim-3202-8. eCollection 2024. Infez Med. 2024. PMID: 38827835 Free PMC article.
  • Casirivimab-imdevimab monoclonal antibody treatment for an immunocompromised patient with persistent SARS-CoV-2 infection: a case report.
    Sam KS, Khosla P, Taneja V, Dessai R. Sam KS, et al. Commun Med (Lond). 2024 Jun 1;4(1):103. doi: 10.1038/s43856-024-00523-w. Commun Med (Lond). 2024. PMID: 38824216 Free PMC article.
  • Long COVID and cardiovascular disease: a prospective cohort study.
    Lawson CA, Moss AJ, Arnold JR, Bagot C, Banerjee A, Berry C, Greenwood J, Hughes AD, Khunti K, Mills NL, Neubauer S, Raman B, Sattar N, Leavy OC, Richardson M, Elneima O, McAuley HJ, Shikotra A, Singapuri A, Sereno M, Saunders R, Harris V, Houchen-Wolloff L, Greening NJ, Harrison E, Docherty AB, Lone NI, Quint JK, Chalmers J, Ho LP, Horsley A, Marks M, Poinasamy K, Evans R, Wain LV, Brightling C, McCann GP; PHOSP-COVID Study Collaborative Group. Lawson CA, et al. Open Heart. 2024 May 27;11(1):e002662. doi: 10.1136/openhrt-2024-002662. Open Heart. 2024. PMID: 38802280 Free PMC article.

References

    1. Callard F, Perego E. How and why patients made long COVID. Soc Sci Med. 2021;268 - PMC - PubMed
    1. Phillips S, Williams MA. Confronting our next national health disaster—long-haul COVID. N Engl J Med. 2021;385:577–579. - PubMed
    1. Crook H, Raza S, Nowell J, Young M, Edison P. Long COVID—mechanisms, risk factors, and management. BMJ. 2021;374 - PubMed
    1. Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4 - PMC - PubMed
    1. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021;53:737–754. - PMC - PubMed

Publication types

Supplementary concepts